Antibodies News and Research

RSS

Study of glycosylation on SARS-CoV-2 spike protein

The first intimation of the current COVID-19 crisis came with the news of severe pneumonic illness caused by an unknown agent in a Chinese city called Wuhan, issued on the last day of 2019. Following this, researchers found the cause to be a novel coronavirus, closely related to the earlier SARS virus, now called severe acute respiratory syndrome coronavirus 2.

8 Jul 2020

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.

7 Jul 2020

Coronavirus study shows herd immunity is infeasible

Herd immunity has been one of the key topics amid the coronavirus pandemic. Previous reports show that when a large proportion of the population gets immune to the novel coronavirus, through vaccination, herd immunity can be achieved.

7 Jul 2020

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

A study conducted by German researchers has shown that the neurological symptoms observed in some patients with coronavirus disease 2019 (COVID-19) may be caused by autoantibodies targeting the brain.

7 Jul 2020

Evolutionary snapshot reveals genetic stability of SARS-CoV-2

A multinational study currently available on the bioRxiv preprint server shows that in the early large genome of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only a handful of amino acids are exchanged, implying a relatively low mutation rate and selection pressure.

7 Jul 2020

Cancer Research UK and Abcam launch custom partnership to accelerate cancer research

Today, Cancer Research UK, the world’s largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents and tools, are pleased to announce a new partnership for the development and commercialization of novel custom antibodies to support the acceleration of cancer research.

From Abcam 7 Jul 2020

Spike proteins of SARS-CoV-2 covered by mobile glycans that shield its surface

A new study of the structural dynamics of the SARS-CoV-2 spike protein published in the preprint server bioRxiv in July 2020 reports on the epitopes that could be possible immune targets for the development of vaccines.

7 Jul 2020

SARS-CoV-2 spike protein hidden as pH changes

Now, a new study published on the preprint server bioRxiv in July 2020 reports the role of pH in helping the virus escape neutralization by antibodies, by inducing a key conformational switch.

7 Jul 2020

Dutch trial of convalescent plasma in COVID-19 discontinued

Now, a recent trial published on the preprint server medRxiv* in July 2020 reports that a majority of hospitalized COVID-19 patients have a high titer of neutralizing antibodies, at the time of admission, within 10 days of symptomatic disease.

7 Jul 2020

Researchers identify immune cell that predicts transplant patient's risk of organ rejection

Researchers at The Ohio State University College of Medicine are the first to identify an immune cell that may predict a transplant patient's risk of developing antibodies that can cause organ rejection.

6 Jul 2020

Human trials of potential COVID-19 vaccine commence in South Australia

A potential COVID-19 vaccine developed at Flinders University has commenced human trials in South Australia.

6 Jul 2020

Cell 'membrane on a chip' could help test potential drug candidates for COVID-19

Researchers have developed a human cell 'membrane on a chip' that allows continuous monitoring of how drugs and infectious agents interact with our cells, and may soon be used to test potential drug candidates for COVID-19.

6 Jul 2020

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

Research suggests protective effect of influenza vaccine against COVID-19 severity and mortality

A new study involving over 92,000 patients with COVID-19 in Brazil shows that the odds of severe disease, ventilatory support requirement, and death are reduced with a recent trivalent flu vaccine. This seems to indicate that these vaccines should be used as widely as possible to reduce the risk of severe COVID-19, especially among high-risk groups. The study is published on the preprint server medRxiv* in June 2020.

5 Jul 2020

Researchers isolate protective antibodies for rare, polio-like disease in children

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

3 Jul 2020

New editorial published following adverse events of gene therapy clinical trial

The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.

3 Jul 2020

Human immune response could neutralize new G virus, shows study

Flashback to mid-March: the novel coronavirus had reached San Diego, California. Few people could get tested, and even less was known about how the virus mutated as it spread from person to person.

3 Jul 2020

Integration of diverse set of species and environments can enhance biomedical research cycle

In an article published today in Science, a multidisciplinary research team from more than 10 universities and research institutes outlines how integrating a more diverse set of species and environments could enhance the biomedical research cycle.

3 Jul 2020

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.

2 Jul 2020

New study supports a causal relation of SARS-CoV-2 with COVID toes

There's considerable controversy over whether "COVID toes"—red sores or lesions on the feet and hands in children and young adults—are truly caused by COVID-19.

2 Jul 2020

Antibodies News and Research

Study of glycosylation on SARS-CoV-2 spike protein

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

Coronavirus study shows herd immunity is infeasible

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

Evolutionary snapshot reveals genetic stability of SARS-CoV-2

Cancer Research UK and Abcam launch custom partnership to accelerate cancer research

Spike proteins of SARS-CoV-2 covered by mobile glycans that shield its surface

SARS-CoV-2 spike protein hidden as pH changes

Dutch trial of convalescent plasma in COVID-19 discontinued

Researchers identify immune cell that predicts transplant patient's risk of organ rejection

Human trials of potential COVID-19 vaccine commence in South Australia

Cell 'membrane on a chip' could help test potential drug candidates for COVID-19

Oxford COVID-19 vaccine trials move to stage 3 human trials

Research suggests protective effect of influenza vaccine against COVID-19 severity and mortality

Researchers isolate protective antibodies for rare, polio-like disease in children

New editorial published following adverse events of gene therapy clinical trial

Human immune response could neutralize new G virus, shows study

Integration of diverse set of species and environments can enhance biomedical research cycle

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

New study supports a causal relation of SARS-CoV-2 with COVID toes

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo